Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Immunocore Holdings Ltd

Healthcare US IMCR

33.34USD
-0.07(0.21%)

Last update at 2026-03-10T20:00:00Z

Day Range

32.4433.85
LowHigh

52 Week Range

41.0176.98
LowHigh

Fundamentals

  • Previous Close 33.41
  • Market Cap2303.03M
  • Volume158646
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-68.19100M
  • Revenue TTM265.27M
  • Revenue Per Share TTM5.38
  • Gross Profit TTM 54.11M
  • Diluted EPS TTM-1.55

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -44.14500M -140.92800M -87.36000M -126.18900M -88.17800M
Minority interest - - - - -
Net income -41.22400M -131.52300M -74.09300M -103.93100M -71.63000M
Selling general administrative 93.72M 88.40M 45.74M 44.18M 34.16M
Selling and marketing expenses - - - 99.99M 83.58M
Gross profit 143.28M 26.52M 30.11M 25.67M 23.65M
Reconciled depreciation 6.13M 7.01M 8.98M 9.21M 6.71M
Ebit -39.60700M -135.16200M -86.19300M -118.32000M -87.65400M
Ebitda -36.45300M -135.11500M -75.44700M -107.71400M -80.94700M
Depreciation and amortization 3.15M 0.05M 10.75M 10.61M 6.71M
Non operating income net other - - - - -
Operating income -39.60700M -135.16200M -86.19300M -118.32000M -93.45500M
Other operating expenses 183.34M 161.68M 119.40M 144.17M 117.73M
Interest expense 7.69M 5.81M 3.11M 3.80M 0.84M
Tax provision -2.92100M -9.40500M -13.26700M -22.25800M -16.54800M
Interest income 3.15M 0.05M 0.71M 1.40M 0.82M
Net interest income -4.53800M -5.76600M -2.40300M -2.40300M -0.02000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.92100M -9.40500M -13.26700M -22.25800M -16.54800M
Total revenue 143.74M 26.52M 30.11M 25.67M 23.65M
Total operating expenses 182.89M 161.68M 119.40M 144.17M 117.73M
Cost of revenue 0.45M - - - -
Total other income expense net -4.53800M -5.76600M -1.16700M -7.86900M 5.92M
Discontinued operations - - - - -
Net income from continuing ops -41.22400M -131.52300M -74.09300M -103.93100M -71.63000M
Net income applicable to common shares -41.22400M -131.52300M -74.09300M -103.93100M -71.63000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 597.00M 435.52M 301.77M 197.19M 185.65M
Intangible assets - 0.00041M - - -
Earning assets - - - - -
Other current assets 9.71M 0.06M 7.69M 6.51M 4.74M
Total liab 228.16M 156.76M 130.23M 141.85M 170.88M
Total stockholder equity 368.84M 278.76M 171.55M 55.35M 14.77M
Deferred long term liab - - - - -
Other current liab 114.32M 0.05M 0.04M 47.17M 5.13M
Common stock 0.14M 0.10M 0.09M 0.00100M -
Capital stock 0.14M 0.10M 0.09M 0.00100M 0.00000M
Retained earnings -744.67400M -261.25300M -481.39200M -349.86900M -279.10600M
Other liab - 5.92M 6.46M 25.01M 48.07M
Good will - 0.41M - - -
Other assets - 11.58M 7.51M 7.22M 6.49M
Cash 442.63M 332.54M 237.89M 129.72M 73.97M
Cash and equivalents - - - - -
Total current liabilities 139.02M 83.09M 61.18M 55.00M 84.51M
Current deferred revenue 5.51M 6.41M 24.45M - 42.55M
Net debt -358.59400M -263.23600M -174.05000M -65.82900M -14.55900M
Short term debt 1.39M 1.55M 1.25M 2.04M 21.11M
Short long term debt - - - - 19.16M
Short long term debt total 84.03M 69.30M 63.84M 63.89M 59.41M
Other stockholder equity 1149.64M 205.16M 266.60M 405.05M 293.91M
Property plant equipment - 31.64M 31.54M 36.85M 54.88M
Total current assets 528.82M 391.88M 262.73M 152.93M 124.28M
Long term investments - 0.14M 0.17M 0.97M 0.59M
Net tangible assets - 278.35M 171.55M 55.35M 14.77M
Short term investments - - - - -
Net receivables 61.44M 58.40M 24.84M 23.21M 50.05M
Long term debt 48.01M 39.50M 37.23M 36.65M -
Inventory 4.50M 0.94M -7.69100M - -
Accounts payable 17.80M 75.08M 35.44M 5.78M 15.73M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -36.26100M 334.75M 386.26M 0.16M -0.03200M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00100M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 14.47M 7.21M 4.77M 4.21M 4.39M
Deferred long term asset charges - - - - -
Non current assets total 68.18M 43.64M 39.05M 44.26M 61.37M
Capital lease obligations 36.02M 29.80M 26.61M 27.23M 40.25M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.19M -0.36700M 0.47M -4.13700M 27.45M
Change to liabilities 18.63M 9.47M -3.77400M 9.95M 5.30M
Total cashflows from investing activities 0.19M -0.36700M 0.47M -4.13700M 58.01M
Net borrowings -3.20800M -3.15900M 33.12M -4.03600M -4.03600M
Total cash from financing activities 138.23M 276.25M 115.94M 55.13M 0.10M
Change to operating activities 0.58M -21.27800M -24.49700M -21.86600M 63.80M
Net income -41.22400M -131.52300M -74.09300M -103.93100M -71.63000M
Change in cash 114.31M 146.03M 55.75M -50.41900M 41.50M
Begin period cash flow 287.30M 175.12M 73.97M 124.39M 82.88M
End period cash flow 401.61M 321.15M 129.72M 73.97M 124.39M
Total cash from operating activities -31.26900M -129.74900M -60.57400M -101.37600M -16.62600M
Issuance of capital stock 116.81M 226.53M 83.22M 59.87M 0.00000M
Depreciation 6.13M 7.01M 8.98M 9.21M 6.71M
Other cashflows from investing activities 2.38M 0.56M 2.87M 0.06M 34.10M
Dividends paid 0.00000M 0.00000M 0.00000M - 0.00000M
Change to inventory - - - - -
Change to account receivables -32.09000M -5.14700M -0.53200M 1.83M -1.52200M
Sale purchase of stock - - - - -
Other cashflows from financing activities 68.13M 52.88M 37.15M -0.71100M 0.10M
Change to netincome 22.09M 45.36M 33.35M 3.43M -19.27800M
Capital expenditures 2.20M 1.01M 3.07M 4.28M 3.54M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -12.88500M -16.80600M -28.80300M -10.09200M 67.58M
Stock based compensation 27.05M 35.86M 8.16M 3.06M 0.67M
Other non cash items -7.42400M -14.88800M 38.45M 22.64M -3.39600M
Free cash flow -33.46600M -130.75700M -63.64800M -105.65200M -20.16300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMCR
Immunocore Holdings Ltd		 -0.07 0.21% 33.34 - - 11.29 6.09 9.49 -45.8153
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings Ltd

92 Park Drive, Abingdon, United Kingdom, OX14 4RY

Key Executives

Name Title Year Born
Dr. Bahija Jallal Ph.D. CEO & Director 1962
Mr. Brian R. Di Donato M.B.A. CFO & Head of Strategy 1967
Ms. Annelise Vuidepot Ph.D. CTO and Head of Pipeline & Platform Research NA
Clayton Robertson Head of Investor Relations NA
Ms. Lily Hepworth Gen. Counsel & Company Sec. NA
Ms. Amy Judge-Prein Chief Compliance Officer NA
Mr. Sébastien Desprez Head of Communications NA
Ms. Tina St. Leger Chief HR Officer 1969
Dr. David Berman M.D., Ph.D. Head of R&D 1971
Ms. Debra Nielsen Chief of Staff NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.